Core Insights - Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and viral infections [1][4] - The company will present at the 10th Annual Innate Killer Summit, highlighting its Decoy platform designed to activate multiple arms of the immune system [2][4] Company Overview - Indaptus Therapeutics has a unique approach based on the hypothesis that effective activation of both innate and adaptive immune cells requires a multi-targeted package of immune system-activating signals [4] - The Decoy platform utilizes attenuated and killed non-pathogenic Gram-negative bacteria to produce a range of immune responses, including activation of Toll-like receptors (TLR), Nucleotide oligomerization domain (NOD)-like receptors (NLR), and Stimulator of interferon genes (STING) agonists [4] - The product candidates have shown promising results in pre-clinical studies, demonstrating activity against various cancers and chronic viral infections [4] Presentation Details - Dr. Michael Newman will present on March 4, 2025, discussing the use of attenuated and killed Gram-negative bacteria to induce NK-mediated anti-tumor immunity [2] - The presentation aims to align with the next generation of immune-based therapies and will be part of a conference focused on advancing NK cell strategies in oncology [2] Research and Development - The Decoy product candidates have demonstrated single-agent activity against metastatic pancreatic and colorectal carcinomas, as well as combination-mediated eradication of hepatocellular carcinomas and non-Hodgkin's lymphomas in pre-clinical models [4] - Pre-clinical studies have shown that the Decoy platform can induce immunological memory and activate both innate and adaptive immune pathways after a single intravenous dose [4] - The company has also observed meaningful activity against chronic hepatitis B virus (HBV) and human immunodeficiency virus (HIV) in pre-clinical models [4]
Indaptus Therapeutics’ Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit